Table 1. Clinical trial outcome.
NA, Not assessed.
| Placebo | l-Arginine | P | |||
| Variable | No. | % | No. | % | |
| Total number of evaluable patients | 32 | 31 | |||
| Radiological responses | |||||
| Complete | 3 | 9.4 | 9 | 29 | 0.059 (C) |
| Partial | 4 | 12.5 | 15 | 48.4 | <0.001 (C + P) |
| Stable | 11 | 34.4 | 4 | 13 | |
| Progression | 5 | 16 | 1 | 3.2 | |
| NA | 9 | 28.2 | 2 | 6.4 | |
| Symptomatic responses | |||||
| Complete | 10 | 31.2 | 25 | 80.6 | |
| Partial | 6 | 18.8 | 4 | 13 | 0.002 (C + P) |
| Stable | 4 | 12.5 | 1 | 3.2 | |
| Progression | 12 | 37.5 | 1 | 3.2 | |
| NA | 0 | 0 | |||
| Overall responses | |||||
| Complete | 3 | 9.4 | 9 | 29 | 0.059 (C) |
| Partial | 4 | 12.5 | 15 | 48.4 | <0.001 (C + P) |
| Stable | 11 | 34.4 | 4 | 13 | |
| Progression | 14 | 43.7 | 3 | 9.6 | |